Berry Plastics Group Inc (NYSE:BERY) up by 3.80%, The Medicines Company (NASDAQ:MDCO)

Posted by Kristi Scott May 13, 2013 0 Comment 1262 views


Berry Plastics Group Inc (NYSE:BERY): Friday’s trading session saw Berry Plastics Group Inc (NYSE:BERY) shares rose by 3.80 %. The opening price of $19.89, moved on to touch an intraday high of $20.96 before sliding down to $19.89 per share. More than 1.17 million shares changed hands in the trading session on Friday. This number was more than the average volume of 0.746 million which was calculated over a 30-day period.

Berry Plastics Group Inc (NYSE:BERY) is an engineered materials and plastic consumer packaging provider.  The company is the owner of 100 percent interest of Berry Plastics Corporation. It operates in three different segments: Rigid Packaging, which is primarily involved in the sales of containers, house wares, over caps, foodservice items, closures, tubes and bottles. Engineered Materials- this sells adhesives, tapes, polyethylene (PE) based film products, laminated coatings, and waste bags. The third segment- Flexible Packaging sells high barrier, multi-layer film products. In June 2012, Berry Plastics Group Inc (NYSE:BERY): acquired 100 percent interest of Franz Nooren Beer B.V. as well as its operating companies (Stupak)

The Medicines Company (NASDAQ:MDCO): Friday’s trading session saw The Medicines Company (NASDAQ:MDCO) shares rising by 3.75 %. The opening price of $36.15, moved on to touch an intraday high of $37.21 before sliding down to $36.10 per share. More than 1.52 million shares changed hands in the trading session on Friday. This number was more than the average volume of 0.767 million which was calculated over a 30-day period.

The Medicines Company (NASDAQ:MDCO) is a pharmaceutical company that is focused on critical care patient treatments. It delivers medicines to the international hospital marketplace. The company markets three products: Cleviprex (clevidipine butyrate) injectable emulsion Angiomax (bivalirudin), as well as a ready-to-use formulation of Argatroban. In addition to this, it has a pipeline of intensive and acute- care hospital products that are in developmental stages. These include three late-stage development-product candidates, oritavancin, MDCO-157and cangrelor.

In 2012 January, The Medicines Company acquired non-exclusive rights to market a portfolio of ten generic drugs in the U.S, from APP Pharmaceuticals, LLC. The company refers to these as its acute-care generic products. In January 2013, it acquired Incline Therapeutics Inc

 


About Kristi Scott

Kristi Scott joined GDP Insider in 2005 as a Wall Street reporter for the Business and Market section. Kristi covers the stock market, financial markets and personal finance. Her awards have come from the National Federation of Professional Writers, the Ohio Newspaper Association, the Cleveland Press Club, the Society of Professional Journalists and Suburban Newspapers of America. Kristi was named SNA's national Journalist of the Year

View all post by Kristi Scott Visit author's website

Write Your Comment